PATENT CLAIM ANALYSIS

Application Number: 15743721
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "396000"]

Abstract:
The present invention relates to IL-8 inhibitor compounds, preferably dual CXCR1/CXCR2 receptor inhibitors, useful in the treatment and/or prevention of interstitial cystitis/painful bladder syndrome (IC/PBS) and/or over active bladder (OAB), also including IC/PBS and/or OAB induced by anticancer therapy. Methods of treatment and/or prevention, combinations and kits comprising said IL-8 inhibitors are also covered therein.

Claim (Index 21):
The method according to  claim 20 , wherein the IL-8 inhibitor is selected from (R,S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino}phenyl)propanoic acid and (2S)-2-(4-{[4-(trifluoromethyl)-1,3-thiazol-2-yl] amino} phenyl) propanoic acid, or a sodium salt thereof.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 86.0
- Lexical Diversity: 1.38298
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['12868790', '10463222', '15795466', '14006771', '10796952']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.777122532854767
- 35 USC 102 Novelty (BERT): 0.502187881476553
- Combined Prediction Score: 0.7496290677169456
- Mean Citation Score: 231.856344
- Max Citation Score: 238.10187
- Similarity Product: 163.77226836591126

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test